🚀 VC round data is live in beta, check it out!
GNI Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for GNI Group and similar public comparables like ACROBiosystems, Guangzhou Innogen Pharma, Savara, Septerna and more.
GNI Group Overview
About GNI Group
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
Founded
2001
HQ
Employees
349
Website
Sectors
Financials (LTM)
EV
$1B
GNI Group Financials
GNI Group reported last 12-month revenue of $181M and negative EBITDA of ($3M).
In the same LTM period, GNI Group generated ($3M) in EBITDA losses and had net loss of ($15M).
Revenue (LTM)
GNI Group P&L
In the most recent fiscal year, GNI Group reported revenue of $175M and EBITDA of ($11M).
GNI Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $181M | XXX | $175M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $126M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 72% | XXX | XXX | XXX |
| EBITDA | ($3M) | XXX | ($11M) | XXX | XXX | XXX |
| EBITDA Margin | (2%) | XXX | (6%) | XXX | XXX | XXX |
| EBIT Margin | (3%) | XXX | (12%) | XXX | XXX | XXX |
| Net Profit | ($15M) | XXX | ($27M) | XXX | XXX | XXX |
| Net Margin | (8%) | XXX | (15%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
GNI Group Stock Performance
GNI Group has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
GNI Group's stock price is $21.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -0.5% | XXX | XXX | XXX | $-0.48 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGNI Group Valuation Multiples
GNI Group trades at 5.7x EV/Revenue multiple, and (331.7x) EV/EBITDA.
EV / Revenue (LTM)
GNI Group Financial Valuation Multiples
As of April 18, 2026, GNI Group has market cap of $1B and EV of $1B.
Equity research analysts estimate GNI Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GNI Group has a P/E ratio of (76.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | (331.7x) | XXX | (94.5x) | XXX | XXX | XXX |
| EV/EBIT | (190.9x) | XXX | (47.5x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.3x | XXX | XXX | XXX |
| P/E | (76.9x) | XXX | (44.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (41.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GNI Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
GNI Group Margins & Growth Rates
GNI Group's revenue in the last 12 month grew by 19%.
GNI Group's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.
GNI Group's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GNI Group's rule of X is 53% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
GNI Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | (2%) | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Growth | (1148%) | XXX | (335%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 68% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 84% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
GNI Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| GNI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ACROBiosystems | XXX | XXX | XXX | XXX | XXX | XXX |
| Guangzhou Innogen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Savara | XXX | XXX | XXX | XXX | XXX | XXX |
| Septerna | XXX | XXX | XXX | XXX | XXX | XXX |
| Inventiva | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GNI Group M&A Activity
GNI Group acquired XXX companies to date.
Last acquisition by GNI Group was on XXXXXXXX, XXXXX. GNI Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by GNI Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGNI Group Investment Activity
GNI Group invested in XXX companies to date.
GNI Group made its latest investment on XXXXXXXX, XXXXX. GNI Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by GNI Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GNI Group
| When was GNI Group founded? | GNI Group was founded in 2001. |
| Where is GNI Group headquartered? | GNI Group is headquartered in Japan. |
| How many employees does GNI Group have? | As of today, GNI Group has over 349 employees. |
| Who is the CEO of GNI Group? | GNI Group's CEO is Ying Luo. |
| Is GNI Group publicly listed? | Yes, GNI Group is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of GNI Group? | GNI Group trades under 2160 ticker. |
| When did GNI Group go public? | GNI Group went public in 2007. |
| Who are competitors of GNI Group? | GNI Group main competitors are ACROBiosystems, Guangzhou Innogen Pharma, Savara, Septerna. |
| What is the current market cap of GNI Group? | GNI Group's current market cap is $1B. |
| What is the current revenue of GNI Group? | GNI Group's last 12 months revenue is $181M. |
| What is the current revenue growth of GNI Group? | GNI Group revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of GNI Group? | Current revenue multiple of GNI Group is 5.7x. |
| Is GNI Group profitable? | No, GNI Group is not profitable. |
| What is the current EBITDA of GNI Group? | GNI Group has negative EBITDA and is not profitable. |
| What is GNI Group's EBITDA margin? | GNI Group's last 12 months EBITDA margin is (2%). |
| What is the current EV/EBITDA multiple of GNI Group? | Current EBITDA multiple of GNI Group is (331.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.